Evidence map›Paper›PMID 29992509›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2018

Understanding osteoporotic pain and its pharmacological treatment: supplementary presentation.

R Vellucci, R Terenzi, J A Kanis, H G Kress, R D Mediati, J-Y Reginster, R Rizzoli, M L Brandi

Open access · greenAbstract readVideo-Audio Media
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

R VellucciDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy.
R TerenziDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy.
J A KanisDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy.
H G KressDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy.
R D MediatiDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy.
J-Y ReginsterDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy.
R RizzoliDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy.
M L BrandiDepartment of Surgery and Translational Medicine, University of Florence, Florence, Italy. marialuisa.brandi@unifi.it.
University of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis, a disorder that affects millions of people worldwide, is characterized by decreased bone mass and microstructural alterations giving rise to an increased risk of fractures. Osteoporotic fractures can cause acute and chronic nociceptive and neuropathic pain that mainly affects elderly patients with multiple comorbidities and commonly on different drug regimens. Central sensitization seems to play a pivotal role in developing and maintaining chronicity of post-fracture pain in osteoporosis. Antiosteoporosis drugs are able to partially control pain, but additional analgesics are always necessary for pain due to bone fractures. Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors reduce acute pain but with a poor effect on the chronic neuropathic component of pain and with relevant side effects. Opioid drugs can control the whole spectrum of acute and chronic bone pain, but they differ with respect to their efficacy on neuropathic components, their tolerability and safety. Chronic pain after osteoporotic fractures requires a multifaceted approach, which includes a large spectrum of drugs (antiosteoporosis treatment, acetaminophen, NSAIDs, selective COX-2 inhibitors, weak and strong opioids) and non-pharmacological treatment. Based on a better understanding of the pathogenesis of osteoporotic and post-fracture pain, a guided stepwise approach to post-fracture osteoporotic pain will also better meet the needs of these patients.

Indexed as

AnalgesicsAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalBone Density Conservation AgentsHumansOsteoporosisOsteoporotic FracturesPainAnalgesicsAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalBone Density Conservation AgentsAnalgesic treatmentChronic painOpioidsOsteoporotic fracture painOsteoporotic pain mechanismOsteoporotic pain treatment

Identifiers

PMID29992509
OpenAlexW2876069149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.